Clinical Challenge: An Underdiagnosed Cause of Resistant Hypertension
Once thought to be rare, the prevalence of primary aldosteronism is estimated to be 5% to 17%, although the condition remains underdiagnosed.
Diagnosis & Disease Information
Evidence-Based Medicine: Tracking Fracking, Hypertension During Pregnancy, and Safety of Eye Surgery
Dr. Ehrlich reviews the evidence of 3 recent studies that evaluate the risk of fracking and health outcomes in infants, management of hypertension in pregnancy, and cardiac risk of eye surgery.
Blood Culture-Negative Endocarditis: Individualized Diagnosis, Management
Primary care providers are the frontline in the prompt identification of potential blood culture-negative endocarditis cases.
A Mysterious Case of Heart Palpitations in Young Woman
A 31-year-old woman with no significant medical history presents with intermittent heart palpitations, dizziness, shortness of breath, and fatigue provoked by exercise. Can you make the diagnosis?
Mavacamten Evaluated in Patients With Obstructive Hypertrophic Cardiomyopathy Eligible for SRT
The VALOR-HCM trial evaluated the effects of mavacamten in over 100 patients with symptomatic obstructive HCM (NYHA class III-IV) who met the guideline criteria for SRT and had been referred for an invasive procedure.
Vasostrict Now Available in Ready-to-Use Formulation
The new formulation is expected to save preparation time.
FDA Supports Qualified Health Claim for Magnesium and Reduced Hypertension Risk
The strength of the scientific evidence supporting the relationship will be disclosed as “supportive but inconclusive” to avoid misleading consumers.
Aficamten Gets Breakthrough Tx Status for Obstructive Hypertrophic Cardiomyopathy
The designation was based on data from the phase 2 REDWOOD-HCM trial.
Acute Pericarditis, Myopericarditis, and Perimyocarditis in Patients With COVID-19
A patient develops pericarditis 19 days after testing positive test for COVID-19. The authors describe how to recognize, diagnose, and treat this condition.
Gene Therapy Gets Orphan Drug Status for Genetic Hypertrophic Cardiomyopathy
TN-201 is a potentially curative, one-time, AAV-based gene therapy to address genetic hypertrophic cardiomyopathy caused by MYBPC3 gene mutations.
- Loading...
Loading...
Loading... 
Loading...